Calyxt

Calyxt, Inc. is technology company. engages in delivering plant-based solutions. Its products include high oleic soybean oil, high fiber wheat, high oleic soybean meal, and low lignin alfalfa. The company was founded by Daniel F. Voytas and André Choulika on January 8, 2010 and is headquartered in Roseville, MN.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cibus, Inc. engages in the research and development of plant traits to seed companies for royalties. It focuses on using gene editing to develop productivity traits in major agricultural crops such as Canola, Rice, Soybean, Corn and Wheat. The company was founded by Rory Riggs, Peter Beetham and Greg Gocal in 2010 and is headquartered in San Diego, CA.

-- Calyxt Announces 1-for-5 Reverse Stock Split of Common Stock -- ROSEVILLE, Minn. , May 19, 2023 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT) ("Calyxt" or the "Company") today announced the results of the special meeting of its stockholders held on May 18, 2023.

Calyxt Announces Stockholder Approval of Merger With Cibus

—P roposed merger with Cibus Global Expected to Close in Q2 2023 — —1-for-10 reverse stock split executed— —Current customer projects under development are on track— —Evologic Technologies completed initial phase of project to scale production of Calyxt's Plant Cell Matrix™ and BioFactoryTM technologies— ROSEVILLE, Minn. , May 1, 2023 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced operating and financial results for its first quarter ended March 31, 2023.

Calyxt Reports First Quarter 2023 Financial Results and Provides Corporate Update

ROSEVILLE, Minn. , April 24, 2023 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT) ("Calyxt" or the "Company") today announced that it has completed the previously announced reverse stock split of Calyxt's common stock, par value $0.0001 per share ("Common Stock"), at a ratio of 1-for-10.

Calyxt Completes One-for-Ten Reverse Stock Split

ROSEVILLE, Minn. and SAN DIEGO , April 18, 2023 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that the registration statement on Form S-4, initially filed with the U.S. Securities and Exchange Commission ("SEC") by Calyxt on February 14, 2023, and amended on April 14, 2023 (as amended, the "Registration Statement"), has been declared effective by the SEC.

Calyxt, Inc. Announces Effectiveness of Registration Statement on Form S-4 in Connection with Merger with Cibus Global LLC

ROSEVILLE, Minn. , April 7, 2023 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT) ("Calyxt" or the "Company") today announced that it will proceed with the 1-for-10 reverse stock split previously approved by the Company's shareholders at the annual meeting of shareholders on June 1, 2022.

Calyxt Announces Effective Date of Reverse Stock Split

NEW ORLEANS , March 9, 2023 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

CALYXT INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Calyxt, Inc. - CLXT

— Announced proposed merger with Cibus Global and filed initial registration statement on Form S-4 —  —Current customer projects under development are on track— —Signed agreement with Evologic Technologies to further develop and scale production of its Plant Cell Matrix™ and BioFactoryTM technologies— ROSEVILLE, Minn. , March 2, 2023 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced operating and financial results for its fourth quarter ended December 31, 2022.

Calyxt Reports Fourth Quarter 2022 Financial Results and Provides Corporate Update

ROSEVILLE, Minn. and SAN DIEGO , Feb. 15, 2023 /PRNewswire/ --  Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that Calyxt has filed a registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC") on February 14, 2023.

Calyxt, Inc. Announces its Filing of Registration Statement on Form S-4 in Connection with Merger with Cibus Global LLC

NEW YORK , Jan. 18, 2023 /PRNewswire/ --  Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Calyxt, Inc. (NASDAQ: CLXT), relating to its proposed merger with Cibus. Under the terms of the agreement, Cibus shareholders are expected to receive new shares of CLXT, with CLXT shareholders expected to own approximately 5% of the combined company.

ALERT: The M&A Class Action Firm Announces the Investigation of Calyxt, Inc. - CLXT

Bed Bath & Beyond

Celyad

How to make money with penny stocks in 2023 The post What Penny Stocks Trends Can Help You Profit in 2023? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What Penny Stocks Trends Can Help You Profit in 2023?

MILWAUKEE , Jan. 18, 2023 /PRNewswire/ -- Ademi LLP is investigating Calyxt (Nasdaq: CLXT) for possible breaches of fiduciary duty and other violations of law in its transaction with Cibus.  Click here to learn how to join the action https://www.ademilaw.com/case/calyxt-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Calyxt, Inc. has entered into a Fair Transaction with Cibus

NEW YORK , Jan. 17, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Calyxt, Inc. ("Calyxt" or the "Company") (NASDAQ: CLXT), in connection with the proposed acquisition of the Company by Cibus ("Cibus"). Under the terms of the merger agreement, the Company will issue shares of its common stock to Cibus shareholders in an exchange ratio such that upon completion of the merger, Calyxt shareholders will only own approximately 5% of the newly combined company while Cibus shareholders will own 95%.

SHAREHOLDER ALERT: Weiss Law Investigates Calyxt, Inc.

Wilmington, Delaware--(Newsfile Corp. - January 17, 2023) - Rigrodsky Law, P.A. is investigating Calyxt, Inc. ("Calyxt") (NASDAQ CM: CLXT) regarding possible breaches of fiduciary duties and other violations of law related to Calyxt's agreement to merge with Cibus Global LLC.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-calyxt-inc. To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Calyxt, Inc. Merger

AIM ImmunoTech Inc

Tritium DCFC Ltd

PLBY Group

SciSparc Ltd

Penny stocks to watch with news that are turning heads in the stock market this week. The post 5 Penny Stocks To Watch After Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Watch After Big News This Week

Calyxt (NASDAQ: CLXT ) stock is rocketing higher on Tuesday after the company signed a merger agreement with Cibus Global. Calyxt and Cibus Global both operate in the agriculture-based gene editing sector.

Why Is Calyxt (CLXT) Stock Up 140% Today?

NEW YORK--( BUSINESS WIRE )--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Calyxt, Inc. (NASDAQ: CLXT) and Cibus is fair to Calyxt shareholders. Under the terms of the merger agreement, Calyxt will issue shares of its common stock to Cibus shareholders in an exchange ratio such that upon completion of the merger, Calyxt shareholders will own approximately 5% of the combined company.

CLXT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Calyxt, Inc. Is Fair to Shareholders

Bioceres Crop Solutions Corp

– The merger will bring together the technology platforms and facilities of two pioneering companies to create a leader in precision gene editing focused on driving sustainable agriculture and the availability of renewable low-carbon ingredients – – Upon closure of the merger, Rory Riggs, Cibus Co-Founder, will become C hief Executive Officer and Chairman of the combined company and the Cibus leadership team will lead the new organization – ROSEVILLE, Minn. and SAN DIEGO , Jan. 17, 2023 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that both companies have entered into a definitive merger agreement under which Calyxt and Cibus will merge in an all-stock transaction.

Calyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing Company

ROSEVILLE, Minn. , Nov. 18, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ: CLXT), a plant-based synthetic biology company announced today that it has successfully completed the first phase in its research collaboration agreement with a leading global food ingredient manufacturer based in Asia to develop an improved soybean capable of producing an oil as a commercial alternative to palm oil.

Calyxt Achieves Phase 1 Milestone in Collaboration Agreement to Develop Alternative to Palm Oil

ROSEVILLE, Minn. , Nov. 17, 2022 /PRNewswire/ -- Calyxt, Inc (Nasdaq: CLXT) a plant-based synthetic biology focused on engineering sustainable ingredients for customers in the cosmeceutical, nutraceutical and pharmaceutical industries, today announced that the Company received written notification from the Listing Qualifications Department of The Nasdaq Stock Market, LLC ("Nasdaq"), granting the Company's request for a 180-day extension to regain compliance with Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule").

Calyxt Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

Calyxt, Inc. (NASDAQ:CLXT ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants William Koschak - CFO Michael Carr - President and CEO Operator Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to Calyxt Third Quarter 2022 Financial Results and Corporate Update Conference Call and Webcast.

Calyxt, Inc. (CLXT) Q3 2022 Earnings Call Transcript

Calyxt (CLXT) delivered earnings and revenue surprises of 13.33% and 86%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Calyxt (CLXT) Reports Q3 Loss, Misses Revenue Estimates

— Successfully produced squalene, an important ingredient for personal care products and vaccine adjuvants— — Continued to progress customer acquisition activities, including evaluating an incremental 37 customer chemistries for development using PlantSpring™ and BioFactory™ technologies— —Signed agreement with Evologic Technologies to further develop and scale production of its Plant Cell Matrix™ technology platform— — Continuing board-level evaluation of a full range of potential strategic alternatives to maximize shareholder value — — Selected for membership to BioMADE, a Department of Defense-sponsored initiative that brings together industrial, academic and non-profit entities to advance US bioindustrial manufacturing — —Management to host conference call and webcast today at 4:30 p.m. ET— ROSEVILLE, Minn.

Calyxt Reports Third Quarter 2022 Financial Results and Provides Corporate Update

-Calyxt joins a select network of synthetic biology companies, top-tier academic institutions, research-focused not-for-profits, and US government agencies dedicated to innovating and growing the bioeconomy- ROSEVILLE, Minn. , Nov. 1, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ: CLXT), a plant-based synthetic biology company, announced today that it has become a member of Bioindustrial Manufacturing and Design Ecosystem (BioMADE), a Department of Defense initiated Manufacturing Innovation Institute dedicated to advancing bioindustrial manufacturing across the nation.

Calyxt Joins Bioindustrial Manufacturing and Design Ecosystem (BioMADE), a Department of Defense Initiative, to Advance Sustainable Plant-Based Biomanufacturing

ROSEVILLE, Minn. , Oct. 27, 2022 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, will host a conference call and webcast on Thursday, November 3, 2022, at 4:30 p.m.

Calyxt to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Thursday, November 3, 2022, at 4:30 p.m. Eastern Time

ROSEVILLE, Minn. , Oct. 25, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ: CLXT), a plant-based synthetic biology company, announced today that using a Calyxt-engineered Plant Cell Matrix™ biomass, it has successfully produced squalene, an important ingredient in many personal care products and vaccine adjuvants, including several strands of flu and COVID-19 vaccines.

News for Calyxt Stock (CLXT)